Rallybio (NASDAQ:RLYB) Announces Quarterly Earnings Results, Beats Estimates By $8.81 EPS

Rallybio (NASDAQ:RLYB) announced its quarterly earnings results on Thursday. The company reported $7.53 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.28) by $8.81, FiscalAI reports. Rallybio had a negative net margin of 911.07% and a negative return on equity of 55.79%.

Rallybio Stock Performance

NASDAQ RLYB traded up $0.05 during trading on Thursday, hitting $16.19. The stock had a trading volume of 27,117 shares, compared to its average volume of 165,800. Rallybio has a one year low of $3.20 and a one year high of $17.57. The stock has a 50 day simple moving average of $15.98 and a 200 day simple moving average of $11.29. The stock has a market capitalization of $85.77 million, a price-to-earnings ratio of -3.73 and a beta of -0.90.

Insider Buying and Selling at Rallybio

In other Rallybio news, major shareholder Adar1 Capital Management, Llc purchased 10,200 shares of Rallybio stock in a transaction dated Tuesday, May 19th. The shares were purchased at an average cost of $13.98 per share, for a total transaction of $142,596.00. Following the completion of the acquisition, the insider owned 926,352 shares in the company, valued at $12,950,400.96. This represents a 1.11% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders purchased 146,568 shares of company stock valued at $2,050,669 in the last quarter. Corporate insiders own 10.30% of the company’s stock.

Hedge Funds Weigh In On Rallybio

Hedge funds have recently bought and sold shares of the business. XTX Topco Ltd boosted its holdings in shares of Rallybio by 64.6% in the 4th quarter. XTX Topco Ltd now owns 97,313 shares of the company’s stock valued at $67,000 after buying an additional 38,205 shares in the last quarter. Susquehanna International Group LLP lifted its position in Rallybio by 485.9% during the third quarter. Susquehanna International Group LLP now owns 136,294 shares of the company’s stock valued at $68,000 after acquiring an additional 113,031 shares during the last quarter. Geode Capital Management LLC boosted its stake in Rallybio by 1.2% in the fourth quarter. Geode Capital Management LLC now owns 248,005 shares of the company’s stock valued at $170,000 after acquiring an additional 2,996 shares in the last quarter. Citadel Advisors LLC grew its holdings in Rallybio by 576.1% in the third quarter. Citadel Advisors LLC now owns 438,705 shares of the company’s stock worth $219,000 after purchasing an additional 373,821 shares during the last quarter. Finally, Renaissance Technologies LLC grew its holdings in Rallybio by 16.9% in the fourth quarter. Renaissance Technologies LLC now owns 835,692 shares of the company’s stock worth $573,000 after purchasing an additional 120,892 shares during the last quarter. Institutional investors own 90.34% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Rallybio in a research report on Friday, May 8th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Rallybio currently has a consensus rating of “Sell”.

About Rallybio

Rallybio Therapeutics, Inc (NASDAQ: RLYB) is a clinical‐stage biotechnology company focused on developing and commercializing therapies for people living with rare genetic diseases. The company’s scientific approach leverages diverse modalities—including monoclonal antibodies, small molecules and enzyme replacement—to address high‐unmet‐need conditions in areas such as immunodeficiency, metabolic disorders and dermatologic diseases. Rallybio’s pipeline is designed to advance through registrational clinical trials with the goal of delivering first‐in‐class or best‐in‐class therapies to patients who currently have limited or no approved treatment options.

Among Rallybio’s lead programs is RBX‐100, an investigational therapy for congenital athymia, a rare pediatric immunodeficiency.